What does this research mean for the field?

Both allogeneic hematopoietic stem cell transplantation and emerging autologous gene therapies provide viable curative options for Sickle Cell Disease, each presenting distinct clinical outcomes, limitations, and challenges regarding equitable global access. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to synthesize the mechanisms of sickle cell disease and evaluate curative therapies, focusing on allogeneic and autologous approaches.

June 14, 2026EncyclopediaOpen Access

The New Era of Curative Therapies for Sickle Cell Disease: A Comprehensive Review of Allogeneic Transplantation and Autologous Gene Therapy

View Full Paper

Ask AI

Bookmark

Authors

AAAhmed AzeezTbilisi State Medical University HVHarshitha VallabhaneniApollo Institute of Medical Sciences & Research ATAdhith TheyverAdvanced Emissions Solutions (United States)

Discussion

Member takes

Overview

Comprehensive review evaluates allogeneic transplantation and autologous gene therapy outcomes in sickle cell disease, suggesting advances in access and treatment efficacy.

Key Points

This review aims to synthesize the mechanisms of sickle cell disease and evaluate curative therapies, focusing on allogeneic and autologous approaches.
Evaluated clinical outcomes of allogeneic hematopoietic stem cell transplantation using various donor sources.
Analyzed autologous gene therapies including lentiviral gene addition and CRISPR-Cas9 editing.
Discussed clinical decision-making paradigms and future innovations for global access.
Allogeneic HSCT offers high survival rates but is limited by donor availability and risk of GVHD.
Autologous gene therapies like Lyfgenia and Casgevy provide innovative, donor-independent options with no GVHD risk.
Emerging therapies may improve access and outcomes for patients with sickle cell disease.

Cite This Study

Azeez et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4608b1cc60ccdea8aec0 https://doi.org/10.3390/encyclopedia6060131

View Full Paper

Ask AI

Bookmark

June 14, 2026EncyclopediaOpen Access

The New Era of Curative Therapies for Sickle Cell Disease: A Comprehensive Review of Allogeneic Transplantation and Autologous Gene Therapy

View Full Paper

Ask AI

Bookmark

Authors

AAAhmed AzeezTbilisi State Medical University HVHarshitha VallabhaneniApollo Institute of Medical Sciences & Research ATAdhith TheyverAdvanced Emissions Solutions (United States)

Discussion

Member takes

Overview

Comprehensive review evaluates allogeneic transplantation and autologous gene therapy outcomes in sickle cell disease, suggesting advances in access and treatment efficacy.

Key Points

This review aims to synthesize the mechanisms of sickle cell disease and evaluate curative therapies, focusing on allogeneic and autologous approaches.
Evaluated clinical outcomes of allogeneic hematopoietic stem cell transplantation using various donor sources.
Analyzed autologous gene therapies including lentiviral gene addition and CRISPR-Cas9 editing.
Discussed clinical decision-making paradigms and future innovations for global access.
Allogeneic HSCT offers high survival rates but is limited by donor availability and risk of GVHD.
Autologous gene therapies like Lyfgenia and Casgevy provide innovative, donor-independent options with no GVHD risk.
Emerging therapies may improve access and outcomes for patients with sickle cell disease.

Cite This Study

Azeez et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4608b1cc60ccdea8aec0 https://doi.org/10.3390/encyclopedia6060131

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark